Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06933251 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

PCSK9 Inhibitor and PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy for pMMR/MSS Locally Advanced Rectal Cancer

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Start date: Jan 20, 2025 to Apr 20, 2025v3
  2. Trial status: Not Yet Recruiting to Active, Not Recruiting
    • Study sites: 1 to 2
    • Start date changed from estimate of May 1, 2025 to Jan 20, 2025
    • Publications: details revised at 2 of 2 entries
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a single-center, open-label, single-arm clinical study aimed at conducting a preliminary evaluation of the efficacy and safety of combining PCSK9 inhibitors and PD-1 inhibitors (dual inhibitors) with neoadjuvant chemoradiotherapy in patients with pMMR/MSS locally advanced rectal cancer.
Trial Details
NCT Number NCT06933251
Lead Sponsor Guangdong Provincial People's Hospital
Conditions
(from sponsor)		 Locally Advanced Rectal Cancer (LARC)
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov